TY - JOUR
T1 - Pharmacokinetic Considerations in the Use of Newer Transdermal Formulations
AU - Ridout, Geoffrey
AU - Santus, Gian Carlo
AU - Guy, Richard H.
PY - 1988/8/31
Y1 - 1988/8/31
N2 - This review addresses the pharmacokinetics and pharmacodynamics of transdermally delivered drugs. The systemic input of drugs via the skin has attracted considerable interest over the past 15 years. The early promise of the administration route has, to some extent, been realised with the approval and successful launching of transdermal formulations of hvoscine (scopolamine), glyceryl trinitrate (nitroglycerin), clonidine and oestradiol. The further application of transdermal delivery, however, will require additional effort.While other molecules (e.g. testosterone, fentanyl, nicotine) may ultimately be administered in this way, important questions pertaining to pharmacology (tolerance), toxicity (irritation, sensitisation) and dose sufficiency (penetration enhancement) remain. These problems are illustrated using information which Has been published in the literature. Overall, while the enthusiasm for attraction and benefits of transdermal delivery remain evident, it is clear that future successes will demand a heightened level of commitment and skill from the pharmaceutical scientist.
AB - This review addresses the pharmacokinetics and pharmacodynamics of transdermally delivered drugs. The systemic input of drugs via the skin has attracted considerable interest over the past 15 years. The early promise of the administration route has, to some extent, been realised with the approval and successful launching of transdermal formulations of hvoscine (scopolamine), glyceryl trinitrate (nitroglycerin), clonidine and oestradiol. The further application of transdermal delivery, however, will require additional effort.While other molecules (e.g. testosterone, fentanyl, nicotine) may ultimately be administered in this way, important questions pertaining to pharmacology (tolerance), toxicity (irritation, sensitisation) and dose sufficiency (penetration enhancement) remain. These problems are illustrated using information which Has been published in the literature. Overall, while the enthusiasm for attraction and benefits of transdermal delivery remain evident, it is clear that future successes will demand a heightened level of commitment and skill from the pharmaceutical scientist.
UR - http://www.scopus.com/inward/record.url?scp=0023707121&partnerID=8YFLogxK
U2 - 10.2165/00003088-198815020-00003
DO - 10.2165/00003088-198815020-00003
M3 - Review article
C2 - 3064951
AN - SCOPUS:0023707121
SN - 0312-5963
VL - 15
SP - 114
EP - 131
JO - Clinical Pharmacokinetics
JF - Clinical Pharmacokinetics
IS - 2
ER -